In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Invitrogen Shows That Not All Life Science is Created Equal

Executive Summary

Invitrogen's performance in 2003 indicates some of the variables involved in determining who can weather the pinch in life sciences spending. The company's experiences indicate that some sectors of life sciences--and thus pharma and biotech R&D--are doing well even if others are not. Invitrogen's cell culture business in particular is growing 30% a year due to changes in the nature of the market, and its new fluorescent probe business, acquired earlier this year, is also doing well.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts